Clinical Trial

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated October 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-07.
Trial Details
NCT Number NCT06633042
Lead Sponsor Bioray Laboratories
Collaborators: Wenzhou Medical University Affiliated Ophthalmology Hospital
Conditions Autoimmune Disease
Enrollment 18 participants
Start Date 2024-11-25
Primary Completion 2025-10-12 (estimated)
Study Completion 2025-12-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-12